UK markets close in 3 hours 13 minutes

Mochida Pharmaceutical Co., Ltd. (MFY.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
17.60+0.10 (+0.57%)
As of 08:23AM CEST. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 636.60M
Enterprise value 360.68M
Trailing P/E 23.40
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.03
Price/book (mrq)0.82
Enterprise value/revenue 0.59
Enterprise value/EBITDA 6.82

Trading information

Stock price history

Beta (5Y monthly) 0.02
52-week change 3-19.72%
S&P500 52-week change 324.52%
52-week high 321.80
52-week low 316.80
50-day moving average 318.22
200-day moving average 319.74

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 535.45M
Implied shares outstanding 636.38M
Float 819.95M
% held by insiders 138.13%
% held by institutions 118.88%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.48
Forward annual dividend yield 42.72%
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 42.51
Payout ratio 463.09%
Dividend date 3N/A
Ex-dividend date 427 Sept 2024
Last split factor 22:1
Last split date 327 Mar 2019

Financial highlights

Currency in JPY.

Fiscal year

Fiscal year ends 31 Mar 2024
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 4.42%
Operating margin (ttm)0.05%

Management effectiveness

Return on assets (ttm)2.28%
Return on equity (ttm)3.57%

Income statement

Revenue (ttm)102.88B
Revenue per share (ttm)2,868.79
Quarterly revenue growth (yoy)12.80%
Gross profit (ttm)N/A
EBITDA 8.61B
Net income avi to common (ttm)4.55B
Diluted EPS (ttm)0.75
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)46.79B
Total cash per share (mrq)1,318.92
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)4.47
Book value per share (mrq)3,607.19

Cash flow statement

Operating cash flow (ttm)-7.48B
Levered free cash flow (ttm)-10.05B